Anticancer Virotherapy May Be Better If Backed by Natural Killer Overkill

They did the math, and then they checked their work—not on paper or in a computer program, but in preclinical tests—to confirm that their immunotherapy proposal added up. The proposal, offered by scientists based at UTHealth, the University of Texas Health Science Center at Houston, was that oncolytic viruses and externally supplied natural killer (NK) cells won’t necessarily work at cross-purposes, as other studies have suggested. Instead, NK cells can improve the cancer-fight